• Intellia Therapeutics first-quarter net loss narrowed to $96.2 million, or $0.81 per share, from $114.3 million, or $1.10 per share, a year earlier.
• Revenue dipped to $15 million from $16.6 million a year earlier, while R&D expense fell to $80.7 million from $108.4 million.
• Cash, cash equivalents and marketable securities totaled $517.2 million at March 31 versus $605.1 million at Dec. 31, plus about $207 million in gross proceeds from an April underwritten public offering.
• Lonvo-z posted positive Phase 3 HAELO topline data, prompting a rolling BLA submission with completion targeted in the second half of 2026 to support a potential U.S. launch in the first half of 2027.
• FDA lifted clinical holds on nex-z Phase 3 MAGNITUDE and MAGNITUDE-2 trials, with patient screening resumed and MAGNITUDE-2 enrollment completion planned for the second half of 2026; existing cash resources expected to fund operations at least into 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intellia Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605110730PRIMZONEFULLFEED9716624) on May 11, 2026, and is solely responsible for the information contained therein.